Thrombolyse im 3- bis 6-Stunden-Zeitfenster nach Schlaganfall

C. Weimar; R. Weber; Z. Katsarava; H.-C. Diener

doi:10.1055/s-2006-951799

Aktuelle Neurologie 2007; 34(1): 40-48
DOI: 10.1055/s-2006-951799

Fort- und Weiterbildung

Thrombolyse im 3- bis 6-Stunden-Zeitfenster nach Schlaganfall

Thrombolytic Therapy within 3 to 6 Hours after Onset of Ischemic StrokeC. Weimar¹ , R. Weber¹ , Z. Katsarava¹ , H.-C. Diener¹

¹

Abstract

Full Text

References

Literatur

1 Heuschmann P U, Berger K, Misselwitz B. et al . Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group. Stroke. 2003; 34 1106-1113
2 Hill M D, Buchan A M. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ. 2005; 172 1307-1312
3 Reed S D, Cramer S C, Blough D. et al . Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke. 2001; 32 1832-1840
4 Hommel M, Boissel P, Cornu C. et al . Termination of trial of streptokinase in severe acute ischemic stroke. Lancet. 1995; 345 357
5 Multicenter Acute Stroke Trial-Italy (MAST-I) Group . Randomised controlled trial of streptokinase, aspirin and combination of both in treatment of acute ischemic stroke. Lancet. 1995; 346 1509-1514
6 Donnan G A, Hommel M, Davis S M, McNeil J J. Streptokinase in acute ischaemic stroke. Steering Committees of the ASK and MAST-E trials. Australian Streptokinase Trial. Lancet. 1995; 346 56
7 The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group . Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333 1581-1587
8 Hacke W, Kaste M, Fieschi C. et al. for the ECASS Study Group . Intravenous thrombolysis with recombinant tissue plasminogen activator for of acute hemispheric stroke. The European cooperative acute stroke study (ECASS). JAMA. 1995; 274 1017-1025
9 Hacke W K, Fieschi M, Kummer C von. et al. for the Second European-Australasian Acute Stroke Study Investigators . Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998; 352 1245-1251
10 Clark W, Wissman S, Albers G. et al., for the ATLANTIS Study Investigators . Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS Study: A randomized controlled trial. JAMA. 1999; 282 2019-2026
11 Hacke W, Kaste M, Fieschi C. et al . Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA. 1995; 274 1017-1025
12 Hacke W, Donnan G, Fieschi C. et al., ATLANTIS Trials Investigators, ECASS Trials Investigators, NINDS rt-PA Study Group Investigators . Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004; 363 768-774
13 Third international stroke trial (IST-3). In: Goldberg MP (ed) Stroke Trials Directory. Internet Stroke Center web site. 07-Aug-2006: http://www.strokecenter.org/trials/TrialDetails.aspx?tid=81
14 ECASS-III .Placebo controlled trial of alteplase (rt-PA) in acute ischemic hemispheric stroke where thrombolysis is initiated between 3 and 4 hours after stroke onset. In: Goldberg MP (ed) Stroke Trials Directory. Internet Stroke Center web site. 07-Aug-2006: http://www.strokecenter.org/trials/TrialDetails.aspx?tid=475
15 Echoplanar imaging thrombolysis evaluation trial (EPITHET). In: Goldberg MP (ed) Stroke Trials Directory. Internet Stroke Center web site. 07-Aug-2006: http://www.strokecenter.org/trials/TrialDetails.aspx?tid=420
16 Hacke W, Albers G, Al-Rawi Y. et al . The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005; 36 66-73
17 Desmoteplase in acute ischemic stroke (DIAS-2). In: Goldberg MP (ed) Stroke Trials Directory. Internet Stroke Center web site. 07-Aug-2006: http://www.strokecenter.org/trials/TrialDetails.aspx?tid=515
18 Ancrod Stroke Program (ASP-II): Ancrod (Viprinex) for the treatment of acute ischemic stroke. In: Goldberg MP (ed) Stroke Trials Directory. Internet Stroke Center web site. 07-Aug-2006: http://www.strokecenter.org/trials/TrialDetails.aspx?tid=701
19 ASP-I. Ancrod (Viprinex) for the treatment of acute ischemic stroke. In: Goldberg MP (ed) Stroke Trials Directory. Internet Stroke Center web site. 07-Aug-2006: http://www.strokecenter.org/trials/TrialDetails.aspx?tid=655
20 Study of efficacy of tirofiban in acute ischemic stroke (SETIS). In: Goldberg MP (ed) Stroke Trials Directory. Internet Stroke Center web site. 07-Aug-2006: http://www.strokecenter.org/trials/TrialDetails.aspx?tid=540
21 Zoppo G J Del, Higashida R T, Furlan A J. et al. and the PROACT Investigators . PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke. 1998; 29 4-11
22 Furlan A, Higashida R, Wechsler L. et al., for the PROACT Investigators . Intra-arterial prourokinase for acute ischemic stroke - The PROACT II Study: A randomized controlled trial. JAMA. 1999; 282 2003-2011
23 Lewandowski C, Frankel M, Tomsick T. et al., and the EMS brigding trial investigators . Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke - Emergency Management of STroke (EMS) brigding trial. Stroke. 1999; 30 2598-2605
24 Local versus systemic thrombolysis for acute stroke (SYNTHESIS). In: Goldberg MP (ed) Stroke Trials Directory. Internet Stroke Center web site. 07-Aug-2006: http://www.strokecenter.org/trials/TrialDetails.aspx?tid=521
25 Imaging-based thrombolysis trial in acute ischemic stroke (ITAIS). In: Goldberg MP (ed) Stroke Trials Directory. Internet Stroke Center web site. 07-Aug-2006: http://www.strokecenter.org/trials/TrialDetails.aspx?tid=680
26 MCA-embolism local fibrinolytic intervention trial (MELT). In: Goldberg MP (ed) Stroke Trials Directory. Internet Stroke Center web site. 07-Aug-2006: http://www.strokecenter.org/trials/TrialDetails.aspx?tid=589
27 Mechanical embolus removal in cerebral ischemia (Multi MERCI). In: Goldberg MP (ed) Stroke Trials Directory. Internet Stroke Center web site. 07-Aug-2006: http://www.strokecenter.org/trials/TrialDetails.aspx?tid=675
28 MR and recanalization of stroke clots using embolectomy (MR RESCUE). In: Goldberg MP (ed) Stroke Trials Directory. Internet Stroke Center web site. 07-Aug-2006: http://www.strokecenter.org/trials/TrialDetails.aspx?tid=559
29 Lees K R, Zivin J A, Ashwood T. et al . NXY-059 for acute ischemic stroke. N Engl J Med. 2006; 354 588-600
30 SAINT II. Stroke - Acute Ischemic - NXY-059 (Cervovive) Treatment. In: Goldberg MP (ed) Stroke Trials Directory. Internet Stroke Center web site. 07-Aug-2006: http://www.strokecenter.org/trials/TrialDetails.aspx?tid=611
31 Thomalla G, Schwark C, Sobesky J. et al . Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials. Stroke. 2006; 37 852-858
32 Ribo M, Molina C A, Rovira A. et al . Safety and efficacy of intravenous tissue plasminogen activator stroke treatment in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke. 2005; 36 602-606

PD Dr. C. Weimar

Klinik für Neurologie, Universitätsklinikum Essen

Hufelandstraße 55

45122 Essen

Email: stroke.med@uni-essen.de